TJ0113
Phase 3Small molecule
TJ0113 is one of 30 small molecule programs targeting Hearing Loss. It is currently in Phase 3.
3
Indications
7
Total Trials
3
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Hearing Loss
#DrugCompanyPhaseTrials
1Cymbalta
Jazz PharmaceuticalsApproved
Cipro
BayerApproved
Medrol
PfizerApproved
Plaquenil
Jazz PharmaceuticalsApproved
Decadron
AAspen Global Incorporated
Approved
Actonel
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Osmitrol
BB. Braun Medical Inc.
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Zonegran
AAzurity Pharmaceuticals
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hearing Loss1 trial
Single Ascending Dose1 trial
Parkinson's Disease1 trial
Efficacy and Safety of TJ0113 Capsule in Patients With Parkinson's Disease
Completed·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06596005·149 enrolled
Depression1 trial
Parkinson's Disease (PD)1 trial
2 more indications
Sarcopenia1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TJ0113. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- HHangzhou PhecdaMed Co., Ltd.